Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

With the addition of CAPLYTA ® to Johnson & Johnson's robust portfolio of therapies, the Company now offers the broadest range of treatment options for adults with schizophrenia. TITUSVILLE, N.J ...

Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Caplyta may cause problems with body temperature, making it difficult for your body to cool down (heat intolerance).Heavy exercise, extreme heat, dehydration, and certain medicines may worsen heat ...

Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression in adults. If you have problems with side effects from Caplyta, talk with your ...

Caplyta may not be safe to take while pregnant or breastfeeding. Keep reading to learn more about Caplyta and reproductive health. And for a detailed overview of this drug, check out this article .

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules. Please click here to see full Prescribing Information including Boxed Warnings. About Johnson & Johnson.